Weekly Investment Analysts’ Ratings Updates for 908 Devices (MASS)

A number of firms have modified their ratings and price targets on shares of 908 Devices (NASDAQ: MASS) recently:

• 8/30/2025 – 908 Devices had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 8/30/2025 – 908 Devices was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 8/22/2025 – 908 Devices was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 8/14/2025 – 908 Devices had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 8/9/2025 – 908 Devices was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 8/5/2025 – 908 Devices was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
• 8/5/2025 – 908 Devices was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $12.00 price target on the stock.
• 7/29/2025 – 908 Devices had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 7/12/2025 – 908 Devices had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insiders Place Their Bets

In other 908 Devices news, insider Michael S. Turner sold 16,082 shares of the business’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $7.51, for a total value of $120,775.82. Following the sale, the insider directly owned 8,521 shares in the company, valued at approximately $63,992.71. The trade was a 65.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joseph H. Iv Griffith sold 6,940 shares of the company’s stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $7.08, for a total transaction of $49,135.20. Following the completion of the sale, the chief financial officer directly owned 102,930 shares of the company’s stock, valued at $728,744.40. The trade was a 6.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,543 shares of company stock valued at $233,890. 23.70% of the stock is currently owned by corporate insiders.

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.